Perimenopause is a decade. Plan accordingly.

The word most women bring into the room is surely. Surely I am too young for this. Surely this is not hormones, my periods are still regular. Surely someone would have told me.

Perimenopause is not a moment. It is a transition that commonly runs four to ten years, and it can begin in the late thirties. Menopause itself is a single retrospective date — twelve consecutive months without a period. Everything before that is the part with the symptoms, and it is the part that gets least attention.

What is actually happening

The intuitive model is that hormones decline steadily. That is not what the transition looks like.

Early on, the ovaries respond less predictably to the brain's signalling. FSH rises to compensate, sometimes recruiting follicles more forcefully, and oestrogen can swing higher than in a woman's thirties — then fall sharply within the same cycle. Progesterone declines earlier and more consistently, because cycles without ovulation become more frequent, and no ovulation means no meaningful progesterone that month.

So the early transition is characterised by volatility rather than deficiency, often with relatively less progesterone against erratic oestrogen. That explains a symptom pattern that otherwise looks contradictory: heavier or closer-together periods alongside hot flushes, new anxiety and disrupted sleep in a woman who is still cycling regularly.

The early transition is not a decline. It is instability — which is why a single hormone measurement so often says nothing useful.

Why the obvious test disappoints

Women frequently arrive having had FSH and oestradiol checked, and having been told the results were normal.

During the transition, both fluctuate enormously from week to week and even day to day. A single draw catches one point on a moving line. A normal FSH in a forty-four-year-old with textbook symptoms rules very little out, and an elevated one on a given day does not establish where she is in the process. Major guidelines are consistent on this: in a woman over about forty-five with characteristic symptoms, perimenopause is a clinical diagnosis. The bloods are not the arbiter.

That does not make testing pointless. It changes what testing is for.

What is worth measuring

The valuable panel here is mostly not the sex hormones. It is everything that mimics them, everything that compounds them, and everything that quietly changes in this decade.

Thyroid, properly — TSH with free T4, free T3 and antibodies. Thyroid disease is markedly more common in women in midlife, and the symptom overlap with perimenopause is close to total.

Ferritin and a full blood count. Heavy or unpredictable bleeding is one of the most common features of the transition, and iron deficiency without anaemia produces exactly the fatigue, breathlessness and hair shedding that get attributed to hormones. It is one of the most satisfying things to find, because it is straightforward to address.

Metabolic and cardiovascular markers. This is the part I most want women to hear. Cardiovascular risk changes meaningfully across the menopausal transition — visceral fat increases, lipids shift unfavourably, insulin sensitivity often declines. Cardiovascular disease is the leading cause of death in women, and the years around menopause are when the trajectory bends. Fasting insulin, HbA1c, ApoB, Lp(a) and hsCRP are worth having as a baseline while there is time to influence what follows.

Vitamin D and bone health. Bone loss accelerates around the final menstrual period. Knowing where someone stands beforehand is more useful than discovering it a decade later.

Sex hormones do get measured, and in the right context they help — particularly where the picture is atypical, where menopause is early, or to track response once a treatment is running. They are simply not the foundation the way most people expect.

Planning for a moving target

The practical consequence of a transition that lasts years is that a plan made once will be wrong before long.

What works in early perimenopause, when the dominant problem is often cycle disruption and relative progesterone insufficiency, is frequently not what works three years later when oestrogen has genuinely declined and the vasomotor symptoms have taken over. A protocol set and left alone tends to drift out of usefulness quietly, and the woman concludes that it stopped working, or that she did.

So we review at intervals rather than at crises, we re-measure the things worth measuring, and we change what needs changing. The point is not to chase a number. It is to keep the plan in contact with a body that is still moving.

Treatment, briefly and honestly

Menopausal hormone therapy is an area where public understanding has lagged badly behind the evidence. The picture shifted after early reporting of a large trial two decades ago, and much of what people believe still dates from that period rather than from the more careful analyses that followed.

What is broadly accepted now is that the balance of benefit and risk depends heavily on a woman's age, how long since her final period, her personal and family history, and the formulation and route used. For many symptomatic women beginning near the transition it is a reasonable option. For some it is not. Non-hormonal approaches exist and work for some women. Sleep, resistance training, alcohol and stress load all move the symptoms more than most people expect.

None of that can be decided by an article. It can only be decided in a conversation with someone who knows your history — which is the case for having the conversation early, rather than at the point where you have spent three years assuming you were imagining it.

This article is educational and is not medical advice, diagnosis, or treatment. Laboratory results and therapies require interpretation in the context of your history, symptoms, medications, and examination, and what is appropriate differs from person to person. Nothing here should be used to start, stop, or change any treatment. Please speak with a qualified clinician who knows your case.